Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Hepatocellular Carcinoma in 2023: What Is New on Pathogenesis, Diagnosis...
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Hepatocellular Carcinoma in 2023: What Is New on Pathogenesis, Diagnosis and Treatment

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 15 May 2024 | Viewed by 5706

Special Issue Editor

Dr. Francesca Romana Ponziani

E-Mail Website
Guest Editor
Internal Medicine and Gastroenterology—Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy
Interests: gut microbiota; liver disease; hepatocellular carcinoma; liver cirrhosis; nonalcoholic fatty liver disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death, and its incidence is increasing globally. Hepatitis B virus and hepatitis C virus infection are major risk factors for the development of HCC. Nonalcoholic fatty liver disease (NAFLD) is a leading cause of hepatocellular carcinoma (HCC).

The tumor microenvironment (TME) is heterogeneous in patients with HCC and is characterized by complex interactions between immune system cells, tumor cells, and other stromal and resident liver cells. The etiology of liver disease plays a role in controlling the TME and modulating the immune response. Markers of immune suppression in the TME are associated with a poor prognosis in several solid tumors. Immunotherapy with immune checkpoint inhibitors (ICIs) has become the main option for treating cancers, including HCC.

This Special Issue aims to provide a platform for molecular mechanistic research on hepatocellular carcinoma with a special focus on potential treatments and novel pathogenic pathways involved in this disease. We warmly welcome your submissions of original papers and reviews based on results from molecular viewpoints.

Dr. Francesca Romana Ponziani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liver cancer
  • hepatocellular carcinoma
  • hepatitis B virus
  • hepatitis C virus
  • nonalcoholic fatty liver disease
  • HBV
  • HCV
  • HCC
  • NAFLD
  • tumor microenvironment
  • gut liver axis

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

14 pages, 760 KiB  
Review
Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends
by Alessandro Posa, Andrea Contegiacomo, Francesca Romana Ponziani, Ernesto Punzi, Giulia Mazza, Annarita Scrofani, Maurizio Pompili, Shraga Nahum Goldberg, Luigi Natale, Antonio Gasbarrini, Evis Sala and Roberto Iezzi
Int. J. Mol. Sci. 2023, 24(8), 7344; https://doi.org/10.3390/ijms24087344 - 16 Apr 2023
Cited by 1 | Viewed by 1607
Abstract
Personalized cancer treatments help to deliver tailored and biologically driven therapies for cancer patients. Interventional oncology techniques are able to treat malignancies in a locoregional fashion, with a variety of mechanisms of action leading to tumor necrosis. Tumor destruction determines a great availability [...] Read more.
Personalized cancer treatments help to deliver tailored and biologically driven therapies for cancer patients. Interventional oncology techniques are able to treat malignancies in a locoregional fashion, with a variety of mechanisms of action leading to tumor necrosis. Tumor destruction determines a great availability of tumor antigens that can be recognized by the immune system, potentially triggering an immune response. The advent of immunotherapy in cancer care, with the introduction of specific immune checkpoint inhibitors, has led to the investigation of the synergy of these drugs when used in combination with interventional oncology treatments. The aim of this paper is to review the most recent advances in the field of interventional oncology locoregional treatments and their interactions with immunotherapy. Full article
(This article belongs to the Special Issue Hepatocellular Carcinoma in 2023: What Is New on Pathogenesis, Diagnosis and Treatment)
►▼ Show Figures

Figure 1

25 pages, 451 KiB  
Review
COVID-19: Has the Liver Been Spared?
by Nicolò Brandi, Daniele Spinelli, Alessandro Granito, Francesco Tovoli, Fabio Piscaglia, Rita Golfieri and Matteo Renzulli
Int. J. Mol. Sci. 2023, 24(2), 1091; https://doi.org/10.3390/ijms24021091 - 06 Jan 2023
Cited by 7 | Viewed by 2913
Abstract
The liver is a secondary and often collateral target of COVID-19 disease but can lead to important consequences. COVID-19 might directly cause a high number of complications in patients with pre-existing chronic liver disease, increasing their risk of hepatic decompensation. Moreover, it also [...] Read more.
The liver is a secondary and often collateral target of COVID-19 disease but can lead to important consequences. COVID-19 might directly cause a high number of complications in patients with pre-existing chronic liver disease, increasing their risk of hepatic decompensation. Moreover, it also determines indirect consequences in the management of patients with liver disease, especially in those suffering from decompensated cirrhosis and HCC, as well as in the execution of their follow-up and the availability of all therapeutic possibilities. Liver imaging in COVID-19 patients proved to be highly nonspecific, but it can still be useful for identifying the complications that derive from the infection. Moreover, the recent implementation of telemedicine constitutes a possible solution to both the physical distancing and the re-organizational difficulties arising from the pandemic. The present review aims to encompass the currently hypothesized pathophysiological mechanisms of liver injury in patients with COVID-19 mediated by both the direct invasion of the virus and its indirect effects and analyze the consequence of the pandemic in patients with chronic liver disease and liver tumors, with particular regard to the management strategies that have been implemented to face this worldwide emergency and that can be further improved. Full article
(This article belongs to the Special Issue Hepatocellular Carcinoma in 2023: What Is New on Pathogenesis, Diagnosis and Treatment)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop